title: Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
abstract: This study compares the sensitivity of a Patient Questionnaire versus information gathered by clinicians at a routine clinic visit in recognizing symptoms of wearing-off in early Parkinson's disease (PD). This Patient Questionnaire, containing 32 items representing a wide spectrum of motor and nonmotor wearing-off symptoms, was administered to subjects attending two PD clinics. The Patient Questionnaire results were compared to the information gathered by the clinician from the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV, Question 36 and from a specific Clinical Assessment Question regarding loss of medication efficacy, wearing-off, sleepiness, dyskinesias, psychiatric complications, morning akinesia, other dopaminergic side effects, or none of the above. Examiners were blinded to study hypothesis and survey contents. Three hundred consecutive subjects with PD of <5 years duration were evaluated; the mean subject age was 72 +/- 9.6 years and 60.2% were men. Subjects reporting wearing-off were significantly younger (69.9 vs. 74.7 years) and differed regarding duration of PD symptoms (3.7 vs. 3.1 years). Wearing-off was found in 181 subjects (62.6%) by one or more of the three measures. The most sensitive tool was the Patient Questionnaire, with 165 subjects (57.1%) indicating symptoms of wearing-off. Question 36 of the UPDRS was positive in 127 subjects (43.9%), and the Clinical Assessment Question identified 85 subjects (29.4%) as experiencing wearing-off. All of these results were found to differ significantly. The mean number of wearing-off symptoms reported by the 165 subjects indicating wearing-off on the clinical survey was 6.25, with tremor being the most common motor feature and tiredness the most common nonmotor feature.
authors.affiliation: Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA. mark.stacy@duke.edu
authors.forename: Mark
authors.initials: M
authors.lastname: Stacy
authors.forename: Annette
authors.initials: A
authors.lastname: Bowron
authors.forename: Mark
authors.initials: M
authors.lastname: Guttman
authors.forename: Robert
authors.initials: R
authors.lastname: Hauser
authors.forename: Kim
authors.initials: K
authors.lastname: Hughes
authors.forename: Jan Petter
authors.initials: JP
authors.lastname: Larsen
authors.forename: Peter
authors.initials: P
authors.lastname: LeWitt
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Oertel
authors.forename: Niall
authors.initials: N
authors.lastname: Quinn
authors.forename: Kapil
authors.initials: K
authors.lastname: Sethi
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Stocchi
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D003072:Cognition Disorders / Q000209:etiology; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009069:Movement Disorders / Q000209:etiology; D017063:Outcome Assessment, Health Care; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D007980:Levodopa